CY1122164T1 - Αξιολογηση και θεραπεια των μεσολαβουμενων απο βραδυκινινη διαταραχων - Google Patents
Αξιολογηση και θεραπεια των μεσολαβουμενων απο βραδυκινινη διαταραχωνInfo
- Publication number
- CY1122164T1 CY1122164T1 CY20181101140T CY181101140T CY1122164T1 CY 1122164 T1 CY1122164 T1 CY 1122164T1 CY 20181101140 T CY20181101140 T CY 20181101140T CY 181101140 T CY181101140 T CY 181101140T CY 1122164 T1 CY1122164 T1 CY 1122164T1
- Authority
- CY
- Cyprus
- Prior art keywords
- mediated
- bradykinin
- evaluation
- treatment
- subject
- Prior art date
Links
- 238000011156 evaluation Methods 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 4
- 108010077861 Kininogens Proteins 0.000 abstract 3
- 102000010631 Kininogens Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
- G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
- G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
- G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361754607P | 2013-01-20 | 2013-01-20 | |
| PCT/US2014/012107 WO2014113712A1 (en) | 2013-01-20 | 2014-01-17 | Evaluation and treatment of bradykinin-mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122164T1 true CY1122164T1 (el) | 2020-07-31 |
Family
ID=51210106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181101140T CY1122164T1 (el) | 2013-01-20 | 2018-11-01 | Αξιολογηση και θεραπεια των μεσολαβουμενων απο βραδυκινινη διαταραχων |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11156612B2 (enExample) |
| EP (3) | EP3456744B1 (enExample) |
| JP (4) | JP6444315B2 (enExample) |
| KR (3) | KR102381478B1 (enExample) |
| CN (2) | CN111044725B (enExample) |
| AU (4) | AU2014207420B2 (enExample) |
| CA (2) | CA3209608A1 (enExample) |
| CY (1) | CY1122164T1 (enExample) |
| DK (1) | DK2948479T3 (enExample) |
| ES (1) | ES2692408T3 (enExample) |
| HR (1) | HRP20181734T1 (enExample) |
| HU (1) | HUE041332T2 (enExample) |
| IL (2) | IL273688B2 (enExample) |
| LT (1) | LT2948479T (enExample) |
| PL (1) | PL2948479T3 (enExample) |
| PT (1) | PT2948479T (enExample) |
| RS (1) | RS57890B1 (enExample) |
| SI (1) | SI2948479T1 (enExample) |
| SM (1) | SMT201800563T1 (enExample) |
| TR (1) | TR201815856T4 (enExample) |
| WO (1) | WO2014113712A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2905545T3 (es) | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| CN111044725B (zh) | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| EP2970502A4 (en) | 2013-03-15 | 2016-11-30 | Dyax Corp | ANTI-PLASMA KALLIKREIN ANTIBODY |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| KR102424183B1 (ko) | 2014-01-21 | 2022-07-26 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| US20180298110A1 (en) * | 2015-03-30 | 2018-10-18 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack |
| JP6903648B2 (ja) * | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
| CN116077648A (zh) * | 2015-12-11 | 2023-05-09 | 武田药品工业株式会社 | 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途 |
| EP3390439B1 (en) * | 2015-12-15 | 2025-03-12 | Takeda Pharmaceutical Company Limited | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk |
| HRP20201131T1 (hr) | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| EP3513196A1 (en) * | 2016-09-16 | 2019-07-24 | Dyax Corp. | Protein biomarkers for diseases associated with the contact activation system |
| MX2019002918A (es) * | 2016-09-16 | 2019-07-18 | Dyax Corp | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| DK3716952T3 (da) | 2017-11-29 | 2022-03-14 | Kalvista Pharmaceuticals Ltd | Doseringsformer omfattende en plasmakallikrein-inhibitor |
| WO2019165308A1 (en) * | 2018-02-22 | 2019-08-29 | The Regents Of The University Of California | Threshold-stimulated plasma kallikrein activity as a biomarker for diagnosis of bradykinin-mediated angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| JP2023521667A (ja) * | 2020-04-04 | 2023-05-25 | 武田薬品工業株式会社 | 血漿カリクレイン阻害剤及び急性呼吸窮迫症候群を処置するためのその使用 |
| CN113777331A (zh) * | 2020-06-09 | 2021-12-10 | 张曼 | 尿液激肽原-1及其多肽片段在烧伤中的应用 |
| EP4548103A2 (en) * | 2022-06-30 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Protein biomarkers for lanadelumab treatment |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1312564C (en) | 1985-07-12 | 1993-01-12 | Robert W. Colman | Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same |
| US5047323A (en) | 1986-01-22 | 1991-09-10 | Temple University Of The Commonwealth System Of Higher Education | Method for detecting human kininogen using monoclonal antibodies thereto |
| US4908431A (en) * | 1986-01-22 | 1990-03-13 | Temple University-Of The Commonwealth System Of Higher Education | Monoclonal antibodies to human kininogen and methods of preparing same |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| KR960009766B1 (ko) | 1986-09-10 | 1996-07-24 | 니혼 소오끼 세이야꾸 가부시기가이샤 | 생리 활성물질 측정법 |
| US4882272A (en) | 1986-10-01 | 1989-11-21 | Temple University - Of The Commonwealth System Of Higher Education | High molecular weight kininogen assay |
| US5025796A (en) | 1988-12-01 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1993003748A1 (en) * | 1991-08-13 | 1993-03-04 | Temple University - Of The Commonwealth System Of Higher Education | Modulation of blood pressure and inhibition of platelet activation with kininogen fragment |
| EP0739355B1 (en) | 1994-01-11 | 2004-09-08 | Dyax Corporation | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| JPH1084995A (ja) | 1996-09-12 | 1998-04-07 | Nippon Zoki Pharmaceut Co Ltd | 血液凝固第ｘｉｉ因子活性化法 |
| US5789261A (en) | 1996-10-30 | 1998-08-04 | Temple University Of The Commonwealth System Of Higher Education | Solid phase immunoassay |
| US6242210B1 (en) | 1997-05-20 | 2001-06-05 | Actinova Limited | Treatment of bacterial infections |
| JP4346798B2 (ja) | 1999-08-19 | 2009-10-21 | 協和メデックス株式会社 | Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。 |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| US7678541B2 (en) | 2000-11-21 | 2010-03-16 | Hologic, Inc. | Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction |
| JP2002221519A (ja) | 2001-01-29 | 2002-08-09 | Sysmex Corp | 抗凝固剤およびそれを用いた抗凝固剤処理方法 |
| US20040152633A1 (en) | 2001-05-31 | 2004-08-05 | Jorgensen Marianne Ulrich | Kunitz-type sequences and polypeptides |
| US6913900B2 (en) | 2001-08-29 | 2005-07-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Plasma prekallikrein activation and kallikrein production assay |
| ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
| WO2004005934A2 (en) * | 2002-07-04 | 2004-01-15 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
| US20070003552A1 (en) | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| US7235530B2 (en) * | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| LT1981519T (lt) | 2005-12-29 | 2018-04-25 | Dyax Corp. | Proteazės slopinimas |
| US7276480B1 (en) | 2005-12-30 | 2007-10-02 | Dyax Corp. | Prevention and reduction of blood loss |
| US7625944B2 (en) | 2006-07-31 | 2009-12-01 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| WO2009026334A2 (en) | 2007-08-21 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2216651A4 (en) * | 2007-10-18 | 2010-12-01 | Miyazaki Prefectural Ind Suppo | BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE |
| WO2009053050A1 (en) | 2007-10-22 | 2009-04-30 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2369930A4 (en) | 2008-12-02 | 2012-10-03 | Joslin Diabetes Ct | METHOD OF REDUCING BLOOD PRESSURE USING PLASMATIC KALLICREIN INHIBITORS |
| AU2013205086A1 (en) * | 2009-01-06 | 2013-05-16 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| FR2942233B1 (fr) | 2009-02-19 | 2015-03-13 | Lfb Biotechnologies | Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre |
| CN102762203A (zh) | 2009-12-18 | 2012-10-31 | 艾克提弗赛特制药股份有限公司 | 血浆激肽释放酶抑制剂的前药 |
| US9206123B2 (en) | 2009-12-18 | 2015-12-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| ES2905545T3 (es) * | 2010-01-06 | 2022-04-11 | Takeda Pharmaceuticals Co | Proteínas de unión a calicreína plasmática |
| EP2593121A2 (en) | 2010-07-13 | 2013-05-22 | University Of Rochester | THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF |
| AU2011336345B2 (en) | 2010-12-02 | 2016-07-07 | Becton, Dickinson And Company | Blood collection devices containing blood stabilization agent |
| IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | Plasma kallikrein binding proteins |
| AU2012267546B2 (en) | 2011-06-10 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| US9187749B2 (en) | 2011-06-10 | 2015-11-17 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| CN111044725B (zh) | 2013-01-20 | 2024-03-29 | 武田药品工业株式会社 | 缓激肽介导的病症的评估和治疗 |
| US20140220552A1 (en) | 2013-02-01 | 2014-08-07 | Becton, Dickinson And Company | Blood collection devices containing contact pathway inhibition additives |
| PT3060908T (pt) | 2013-10-21 | 2021-05-27 | Dyax Corp | Diagnóstico e tratamento de doenças autoimunes |
| KR20250066486A (ko) | 2013-10-21 | 2025-05-13 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법 |
| KR102424183B1 (ko) | 2014-01-21 | 2022-07-26 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| JP6903648B2 (ja) | 2015-10-19 | 2021-07-14 | ダイアックス コーポレーション | 切断高分子量キニノーゲンを検出するイムノアッセイ |
-
2014
- 2014-01-17 CN CN201911415224.8A patent/CN111044725B/zh active Active
- 2014-01-17 KR KR1020217000831A patent/KR102381478B1/ko active Active
- 2014-01-17 PT PT14740444T patent/PT2948479T/pt unknown
- 2014-01-17 WO PCT/US2014/012107 patent/WO2014113712A1/en not_active Ceased
- 2014-01-17 KR KR1020157022389A patent/KR102203880B1/ko active Active
- 2014-01-17 JP JP2015553864A patent/JP6444315B2/ja active Active
- 2014-01-17 SM SM20180563T patent/SMT201800563T1/it unknown
- 2014-01-17 RS RS20181235A patent/RS57890B1/sr unknown
- 2014-01-17 PL PL14740444T patent/PL2948479T3/pl unknown
- 2014-01-17 US US14/761,690 patent/US11156612B2/en active Active
- 2014-01-17 ES ES14740444.6T patent/ES2692408T3/es active Active
- 2014-01-17 SI SI201430933T patent/SI2948479T1/sl unknown
- 2014-01-17 CA CA3209608A patent/CA3209608A1/en active Pending
- 2014-01-17 DK DK14740444.6T patent/DK2948479T3/en active
- 2014-01-17 EP EP18186356.4A patent/EP3456744B1/en active Active
- 2014-01-17 IL IL273688A patent/IL273688B2/en unknown
- 2014-01-17 EP EP23164279.4A patent/EP4234583A3/en active Pending
- 2014-01-17 KR KR1020227010217A patent/KR102523810B1/ko active Active
- 2014-01-17 AU AU2014207420A patent/AU2014207420B2/en active Active
- 2014-01-17 TR TR2018/15856T patent/TR201815856T4/tr unknown
- 2014-01-17 LT LTEP14740444.6T patent/LT2948479T/lt unknown
- 2014-01-17 HR HRP20181734TT patent/HRP20181734T1/hr unknown
- 2014-01-17 HU HUE14740444A patent/HUE041332T2/hu unknown
- 2014-01-17 EP EP14740444.6A patent/EP2948479B1/en active Active
- 2014-01-17 CN CN201480005158.6A patent/CN105073778B/zh active Active
- 2014-01-17 CA CA2897336A patent/CA2897336C/en active Active
-
2015
- 2015-06-15 IL IL239428A patent/IL239428B/en active IP Right Grant
-
2018
- 2018-11-01 CY CY20181101140T patent/CY1122164T1/el unknown
- 2018-11-07 AU AU2018260845A patent/AU2018260845B2/en active Active
- 2018-11-27 JP JP2018221155A patent/JP6772237B2/ja active Active
-
2020
- 2020-09-30 JP JP2020164435A patent/JP2021008483A/ja active Pending
- 2020-11-25 AU AU2020277178A patent/AU2020277178B2/en active Active
-
2021
- 2021-10-01 US US17/491,813 patent/US20220170936A1/en active Pending
-
2022
- 2022-02-28 JP JP2022029441A patent/JP7496380B2/ja active Active
-
2024
- 2024-08-09 AU AU2024205664A patent/AU2024205664A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122164T1 (el) | Αξιολογηση και θεραπεια των μεσολαβουμενων απο βραδυκινινη διαταραχων | |
| CY1121872T1 (el) | Αξιολογηση, δοκιμασιες και θεραπεια των pkal-μεσολαβουμενων διαταραχων | |
| CY1120434T1 (el) | Πρωτεϊνες προσδεσης il-1 | |
| CY1124299T1 (el) | Συνδυαστικες θεραπειες που περιλαμβανουν μορια αντισωματων κατα toy lag-3 | |
| BR112014031365A2 (pt) | métodos de detectar doenças ou condições | |
| CY1123833T1 (el) | Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου | |
| ZA202000935B (en) | Methods and materials for assessing and treating cancer | |
| PH12020500163A1 (en) | A system and method for non-invasively determining egg properties | |
| CY1121341T1 (el) | Δοκιμες για την ανιχνευση της παρουσιας ή της ποσοτητας αντισωματος κατα αντισωματος φαρμακου | |
| CY1122510T1 (el) | Μορια αντισωματος σε lag-3 και χρησεις αυτων | |
| CY1120423T1 (el) | Β7-η1 και pd-1 στη θεραπεια του καρκινωματος νεφρικων κυτταρων | |
| CY1119510T1 (el) | Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης | |
| CY1118748T1 (el) | Πολυπλεγμενοι προσδιορισμοι βασιζομενοι σε απταμερη | |
| EP3798616A4 (en) | Chemical luminescence analysis and measurement method, system using same, and kit | |
| CY1118694T1 (el) | Μεθοδοι διαχωρισμου σωματιδιων χρησιμοποιωντας μια συσκευη με ενα στοιχειο διαχωρισμου με διακριση μεγεθους που εχει μια επιμηκη αιχμη | |
| CL2017003069A1 (es) | Métodos para diagnosticar y tratar el cáncer. | |
| EP3383793A4 (en) | TECHNIQUES FOR THE QUANTUM ERROR CORRECTION USING BOSTON-MODEN AND RELATED SYSTEMS AND METHODS | |
| CY1118660T1 (el) | Συνθεσεις και μεθοδοι για την θεραπεια διαταραχων ματιων | |
| CY1117095T1 (el) | Συσκευη και μεθοδος για ηλεκτροχημικη ανιχνευση | |
| CY1120346T1 (el) | Συνδυασμος φαρμακων | |
| EP2689386A4 (en) | PERSONALIZED DEVICES, METHODS AND SYSTEMS FOR PURCHASING AT THE BUTTON PRESSURE | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| MX382410B (es) | Determinación de niveles de glicosaminoglicanos mediante espectrometría de masas. | |
| CY1125020T1 (el) | Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων | |
| HK1247250A1 (zh) | 用於指导癌症治疗的内容相关的诊断测试 |